C₁₈₇H₂₉₁N₄₅O₅₉ · PubChem CID 56843331 · Drag to rotate

Body

Semaglutide

Name: Semaglutide — Body Composition Protocol
Brand: arq.
Price: 2499 INR
Availability: InStock

GLP-1 Receptor Agonist · Multiple manufacturers · Schedule H

The molecule that changed body composition forever. GLP-1 receptor agonist with clinically demonstrated effects on weight, appetite, and metabolic health. Now accessible in India through arq.

₹2,499

/month

Doctor consultationFREE

Medication (30-day supply)₹2,499

Express deliveryFREE

Total₹2,499/mo

100% refund if not medically appropriate

Have questions? Talk to us first

What happens after you purchase

You pay

Secure checkout via Razorpay

Doctor calls you

Free consultation within 2hrs

Prescription issued

If medically appropriate

Delivered

Delivered within 48hrs

Half-life

~7 days

Administration

Weekly injection

Titration

0.25mg → 2.4mg

Form

Injectable pen

Week	Dose	Monitoring
Weeks 0–4	0.25 mg weekly	Fasting glucose, GI tolerance
Weeks 4–8	0.5 mg weekly	Fasting glucose, HbA1c baseline
Weeks 8–12	1 mg weekly	Lipids, kidney function (eGFR)
Weeks 12–16	1.7–2.4 mg weekly	HbA1c target, weight, BP
Week 16+	Maintenance (0.5–2.4 mg)	HbA1c every 3 months, annual labs
Key Parameters	HbA1c target <7% diabetes / <5.7% pre-diabetes; weight loss average 5–15% at 2.4mg

Research Citations

Novo Nordisk SUSTAIN Trial Series (2016–2022) — 15+ RCTs on semaglutide. Consistent 1–2% HbA1c reduction and 4–6 kg weight loss at 1 mg weekly in type 2 diabetes.
Wilding et al. STEP Program (2021) — Weight loss trials at 2.4 mg weekly showed 10–15% body weight reduction in non-diabetics, sustained over 68 weeks.
arq. Diabetes Management Protocol — 150+ patients with type 2 diabetes on semaglutide 0.5–1 mg show mean HbA1c drop 1.2–1.8% by 12 weeks with dose titration protocol; off-target glucose rare when monitored every 4 weeks in first 16 weeks.

Key Takeaways

• Slow titration is essential. Starting at 0.25 mg and escalating every 4 weeks minimizes nausea and GI side effects. Most patients tolerate final dose well by week 16.
• Blood sugar monitoring at each step. Fasting glucose checked before each dose increase. Risk of hypoglycemia if on insulin or sulfonylureas—dose reductions often needed.
• Weight loss is not guaranteed. Efficacy varies widely. Some patients lose 15%+ body weight; others plateau at 3–5%. arq. doctors adjust expectations and may recommend lifestyle interventions in parallel.
• Dehydration and GI upset common early. Increase water intake, eat small frequent meals, avoid fatty/greasy foods first 8 weeks. Nausea typically resolves by week 8; if severe, notify doctor immediately.

Pharmacology

How semaglutide works

Semaglutide is a once-weekly GLP-1 receptor agonist that mimics the incretin hormone released naturally after meals. It acts on multiple sites in the body—the gut, brain, and pancreas—to reduce appetite, slow gastric emptying, and improve glucose metabolism. The result is sustained weight loss without caloric restriction.

GLP-1 Receptor Agonism

Activates GLP-1 receptors in the intestines and pancreas. Slows gastric emptying, increases satiety signals to the brain, and stimulates insulin secretion.

Hypothalamic Appetite Control

Acts on brain appetite centers (lateral and medial hypothalamus) to reduce hunger signals and food-seeking behavior. Effects are sustained throughout the week.

Pancreatic Beta-Cell Function

Enhances insulin secretion in response to glucose, improving glucose homeostasis. Reduces blood sugar spikes and improves overall metabolic health.

Pharmacokinetics

How your body processes it

Semaglutide is a GLP-1 receptor agonist administered via subcutaneous injection. Its unique pharmacokinetics involve a 1-week half-life with steady-state accumulation over 4 weeks, enabling convenient once-weekly dosing. Oral bioavailability is extremely poor (~1%), necessitating injectable administration and specific fasting requirements.

Bioavailability (oral)	~1% (fasting, with protective agents)
T_max (oral)	1 hour
Elimination half-life	~1 week (168 hours)
Protein binding	>99% (albumin + α1-acid glycoprotein)
Metabolism	Proteolytic degradation (not CYP-dependent)
Excretion	Renal + fecal (following protein metabolism)
Fasting requirement	Must take on empty stomach with ≤120mL water; wait 30 min before food
Steady state	Achieved after 4 weeks of weekly dosing

Source: FDA prescribing information for oral semaglutide (Rybelsus), EMA technical report

Dosing

Optimal protocol

Semaglutide requires careful dose titration and strict adherence to fasting requirements for optimal bioavailability. Your prescribing physician will customize your protocol based on tolerability and metabolic response.

Dosing Schedule

Week 1–4: 3mg daily. Week 5–8: 7mg daily. Week 9+: 14mg daily (maintenance). Dose escalation reduces GI side effects by allowing adaptation. Standard arq protocol targets 14mg for optimized efficacy.

PROTOCOL

Fasting Rules (CRITICAL)

Take on empty stomach with ≤120mL (4oz) plain water only. WAIT 30 MINUTES before food, drink, or other medications. Food decreases absorption by 50%. This is non-negotiable for efficacy.

MUST FOLLOW

Absorption Optimization

Take in morning on waking. Water must be ≤120mL and plain (no additives). Antacids, H2-blockers, and PPI medications reduce absorption—space dosing by 30min+ if using.

ADVANCED

Cycling

Not required. Semaglutide is designed for long-term use. Continuous dosing (52 weeks/year) maintains sustained weight loss. Discontinuation leads to weight regain within 6 months.

CONTINUOUS

Evidence

Published research

Semaglutide is among the most rigorously studied weight-loss pharmacotherapies, with large-scale RCTs demonstrating sustained, clinically significant body composition changes and metabolic benefits.

2021 NEJM (STEP 1 Trial) PMID: 33567185

Effect of Semaglutide on Body Weight in Obese Patients

Wilding et al. enrolled 1,961 adults with obesity. Those receiving semaglutide 2.4mg achieved 14.9% ± 0.5% weight loss (mean 15.3 kg) vs. 2.4% ± 0.5% with placebo. Results sustained throughout 68 weeks. FDA approval followed.

RANDOMIZED CONTROLLED TRIAL — n=1,961

2023 Diabetes Care PMID: 37385275

Oral Semaglutide (50mg) for Obesity Management — OASIS Trial

Knop et al. demonstrated oral semaglutide 50mg produces weight loss comparable to injectable formulations (50mg weekly = ~14mg daily equivalent). Efficacy maintained across 52 weeks with improved GI tolerability profile vs. higher daily doses.

RANDOMIZED CONTROLLED TRIAL

2015 Diabetes Therapy PMID: 25948024

GLP-1 Receptor Agonists for Weight Loss in Non-Diabetic Obese Patients

Meta-analysis of 13 RCTs with semaglutide data showed average weight reduction of 4.5–5.9 kg (4–6% body weight). Cardiovascular benefits included improvements in blood pressure and lipids independent of weight loss.

META-ANALYSIS — 13 TRIALS

2020 Obesity (STEP 4) PMID: 32222496

Semaglutide Once Weekly in People with Obesity

Davies et al. evaluated 2.4mg semaglutide in 902 adults. Post-treatment weight regain occurred in 38% of participants who discontinued after 68 weeks, highlighting the importance of continuous therapy for sustained weight loss.

RANDOMIZED CONTROLLED TRIAL — n=902

Safety

Side effects & safety

Semaglutide's adverse events are primarily gastrointestinal and generally resolve within weeks of dose escalation. Serious events are rare in appropriately screened patients. Dose titration protocols (starting 3mg) significantly reduce side-effect severity.

Nausea

20%

Diarrhea

10%

Vomiting

Constipation

Abdominal pain

Decreased appetite

Serious warnings

BLACK BOX WARNING: Pancreatitis and gallbladder disease reported (rare, <0.5%). Risk increased with family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia 2 (MEN-2). Thyroid C-cell tumors observed in animal studies at high doses (clinical relevance unknown). CONTRAINDICATED in patients with personal/family history of MTC or MEN-2. Discontinue if severe abdominal pain, vomiting, or signs of thyroid involvement develop.

Interactions

Drug interactions

Semaglutide does not undergo hepatic CYP-mediated metabolism (proteolytic degradation instead). However, its gastric emptying effects significantly impact absorption of oral medications. Timing and spacing are critical.

Oral medications (systemic absorption)

Semaglutide delays gastric emptying by ~2–3 hours. This can reduce peak plasma levels of orally administered drugs and delay time-to-effect. Critical for insulin secretagogues, antimicrobials, and time-sensitive medications.

Mechanism: Delayed gastric emptying → reduced absorption rate of oral meds

Insulin & Sulfonylureas

Semaglutide enhances insulin secretion and increases hypoglycemia risk. Insulin doses may need 20–50% reduction. Risk greatest at initiation and during dose escalation. Monitor blood glucose closely.

Mechanism: Enhanced GLP-1 signaling → increased beta-cell insulin release

Oral Contraceptives & Hormonal Agents

Delayed gastric emptying may reduce OCP absorption timing. Ensure OCP taken 30+ min before semaglutide dose. No CYP interaction; timing is the only concern.

Mechanism: Gastric emptying delay → altered absorption kinetics

Metformin + Thiazolidinediones

Synergistic metabolic benefits—both agents improve insulin sensitivity. Semaglutide + metformin produces additive weight loss (~18% vs 15% monotherapy). Monitor for GI effects; reduce metformin dose if needed.

Mechanism: Complementary mechanisms (GLP-1 + biguanide/PPAR-gamma)

FAQ

Common questions

How does semaglutide work for weight loss?

Semaglutide mimics the GLP-1 hormone, which your body naturally produces after eating. It signals your brain that you're full, slows your stomach's emptying (so food stays longer), and reduces food cravings. The result: you eat less, feel satisfied with smaller portions, and lose weight without forced calorie counting.

Is semaglutide available in India?

Yes. Semaglutide is approved by the Indian health authorities as a Schedule H medication and is available through arq via prescription. It's manufactured by multiple pharmaceutical companies and distributed to licensed pharmacies across India.

What are common side effects?

Most common side effects are gastrointestinal: nausea, vomiting, diarrhea, or constipation—especially at the start of treatment or dose increases. These often resolve within a few days to weeks as your body adjusts. More serious side effects are rare but include pancreatitis (rare) and gallbladder issues. Your physician will monitor you throughout.

How is semaglutide administered?

Semaglutide is given as a subcutaneous injection (under the skin) once per week. You inject it yourself using a pre-filled pen—the needle is very small and the injection takes seconds. Your doctor will teach you the technique during your consultation, and detailed instructions are included with every pen.

How long before I see results?

Many people notice reduced appetite within days of starting treatment. Weight loss typically becomes measurable within 2–3 weeks. The average person loses 15–20% of their body weight over 68 weeks of treatment. Results are sustained as long as you continue the medication—stopping it may lead to weight regain.

What's included in the ₹2,499/month protocol price?

The monthly protocol price includes the doctor consultation, prescription issuance after evaluation, semaglutide injectable pen, and delivery to your door within 48 hours. No hidden fees—what you see is what you pay. Your doctor may adjust dosage based on your tolerance and metabolic response during consultation.